Table 4.
Rate ratios of venous thromboembolism between users of combined oral contraceptives with different progestogens according to certainty of diagnosis of venous thromboembolism
| Comparison groups | No of events* | Rate ratio† | P value | |
|---|---|---|---|---|
| Partially adjusted | Fully adjusted‡ (95% CI) | |||
| Confirmed events | ||||
| Drospirenone + 30 μg EE versus: | ||||
| Levonorgestrel + 30-40 μg EE (all) | 196 v 123 | 2.03 | 2.12 (1.68 to 2.66) | <0.001 |
| Levonorgestrel + 30 μg EE (without phasic preparations) | 196 v 57 | 2.08 | 2.18 (1.62 to 2.94) | <0.001 |
| Third generation progestogens§ | 196 v 743 | 0.98 | 1.01 (0.86 to 1.18) | 0.9248 |
| Desogestrel + 30 μg EE v levonorgestrel + 30-40 μg EE | 168 v 123 | 2.18 | 2.20 (1.74 to 2.77) | <0.001 |
| Gestodene + 30 μg EE v levonorgestrel + 30-40 μg EE | 575 v 123 | 2.04 | 2.07 (1.70 to 2.52) | <0.001 |
| Non-confirmed events | ||||
| Drospirenone + 30 μg EE versus: | ||||
| Levonorgestrel + 30-40 μg EE | 70 v 44 | 1.71 | 1.78 (1.21 to 2.60) | 0.0032 |
| Levonorgestrel + 30 μg EE (without phasic preparations) | 70 v 21 | 1.70 | 1.78 (1.09 to 2.91) | 0.0213 |
| Third generation progestogens§ | 70 v 196 | 1.25 | 1.27 (0.97 to 1.68) | 0.0840 |
| Desogestrel + 30 μg EE v levonorgestrel + 30-40 μg EE | 33 v 44 | 1.10 | 1.10 (0.70 to 1.73) | 0.6764 |
| Gestodene + 30 μg EE v levonorgestrel + 30-40 μg EE | 163 v 44 | 1.45 | 1.47 (1.05 to 2.06) | 0.0236 |
EE=ethinylestradiol.
*Events are venous thromboembolisms.
†Adjusted for age and calendar year.
‡Adjusted for age, calendar year, and level of education.
§Desogestrel or gestodene.